FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer (READ MORE HERE).
Application of Nanotechnology to Novel Models of..
University of North Carolina
Identification of molecular drivers of prostate cancer..
Dr. Efsathiou earned both MD and PhD..
Eleni Efstathiou, MD, PhD:
The University of Texas MD Anderson Cancer Center – Houston, TX
Molecular imaging of prostate cancer to determine..
Michael Evans, PhD:
University of California, San Francisco
Charles Sawyers, MD and Jason Lewis, PhD
Exploiting the genetics of advanced prostate cancer for tumor detection and therapy with transferrin-based radionuclides
Jason A. Efstathiou, MD, DPhil:
Massachusetts General Hospital
Matthew R. Smith, MD, PhD
Predictors of Response and Failure to Radiotherapy for Prostate Cancer in a Randomized Trial
Ederer Investment Company
Evans & Co., LLC is a multi-purpose..
President & Managing Partner of Evans & Co., LLC
Flintridge Capital Investments, LLC